



Meeting Agenda

Group: ISPOR 36th HTA Roundtable – Asia-Pacific			
Date: Saturday, September 23, 2017		Time: 8:30AM-5:00PM	
Meeting Location: Residence Room (2nd floor), Grand Hyatt Taipei, Taipei, Taiwan			
Invitees: Sukyeong Kim, Chee-Jen Chang, Yen-Huei (Tony) Tarn, Finn Børllum Kristensen, Stephen Goodall, Kun Zhao, Jitendar Sharma, Agusdini Banun, Roy Himawan, Roni Syahputra, Hiroyuki Sakamaki, Ruoyan Gai, Temirkhan Kulkhan, Izzuna Mudla Mohamed Ghazali, Tsetsegmaa Sanjjav, Richard Milne, Merla Rose D. Reyes, Gemma Vecina, Kern Rei Chng, Churn-Shiouh Gau, Mao-Ting Sheen, Jaw-Jou Kang, Raoh-Fang (Jasmine) Pwu, Netnapis Suchonwanich, Suradech Dounghtipsirikul, Tuan Quang Kieu			
Item #	Time	Topic	Discussion Leader(s)/ Presenter(s)
1	8:30-8:50	Welcome & Introduction <ul style="list-style-type: none"> Welcome from Roundtable Co-Chairs Welcome from ISPOR ISPOR Presentation Delegate Introduction 	Sukyeong Kim, Chee-Jen Chang, Yen-Huei (Tony) Tarn Nancy Berg Robert Selby All delegates
2	8:50-10:30 8:50-9:05 9:05-9:20 9:20-9:35 9:35-9:50 9:50-10:05 10:05-10:15 10:15-10:30	HTA in Medical Devices and Diagnostics <ul style="list-style-type: none"> Australia India China South Korea Japan Japan (Perspectives of HTA in Child Health) Mongolia 	Sukyeong Kim Stephen Goodall Jitendar Sharma Kun Zhao Sukyeong Kim Hiroyuki Sakamaki Ruoyan Gai Tsetsegmaa Sanjjav
3	10:30-10:40	Coffee / Tea Break	
4	10:40-11:30	Discussion Session I (Refer to last page)	Sukyeong Kim & All
5	11:30-12:30 11:30-11:45 11:45-12:00 12:00-12:15 12:15-12:30	HTA of Medical Devices and Diagnostics <ul style="list-style-type: none"> Taiwan CDE Taiwan NHIA Kazakhstan New Zealand 	Chee-Jen Chang Churn-Shiouh Gau Mao-Ting Sheen Temirkhan Kulkhan Richard Milne
6	12:30-1:30	Lunch	Café Restaurant (lobby floor)



Meeting Agenda

7	1:30-1:45	HTA in ISPOR (Remote presentation) <ul style="list-style-type: none">• ISPOR HTA Council: HTA activities and training programs• Updates on HTA in Europe: EUnetHTA perspective	Finn Børllum Kristensen
8	1:45-2:35	Discussion Session II (Refer to last page)	Chee-Jen Chang & All
9	2:35-3:50	HTA of Medical Devices and Diagnostics in ASEAN (Singapore as an observer)	Yen-Huei (Tony) Tarn
	2:35-2:50	• Indonesia	Agusdini Banun
	2:50-3:05	• Malaysia	Izzuna Mudla Mohamed Ghazali
	3:05-3:20	• Philippines	Merla Rose D. Reyes
	3:20-3:35	• Vietnam	Tuan Quang Kieu
	3:35-3:50	• Thailand	Netnapis Suchonwanich
10	3:50-4:00	Coffee / Tea Break	
11	4:00-4:50	Discussion Session III (Refer to last page)	Yen-Huei (Tony) Tarn & All
12	4:50-5:00	Wrap-up	Sukyeong Kim, Chee-Jen Chang, Yen-Huei (Tony) Tarn

Welcome Dinner Banquet

Location: Yun Jin Chinese Restaurant, 2nd floor of the Grant Hyatt Taipei

Day and Time: 6:30pm - 9:00pm, Friday, 22 September, 2017

ISPOR Website: <https://www.ispor.org/>
ISPOR Asia Consortium: <https://www.ispor.org/consortiums/asia.asp>



Discussion Topics/Questions

Discussion Session I (Moderated by Dr. Sukyeong Kim)

- What unique challenges does HTA on medical devices present compared to pharmaceuticals? How do these challenges make medical devices more difficult to get through the regulatory process and achieve a successful market access?
- Do we need different HTA approaches for medical devices? What are the most commonly used methods for the HTA of medical devices in your country/region?
- What are the main criteria for prioritizing medical devices for HTA in your country?

Discussion Session II (Moderated by Dr. Chee-Jen Chang)

- Is there a need for HTA cooperation and harmonization (pharmaceuticals & medical devices) in the Asia-Pacific region? What are the current barriers, challenges, and opportunities?
- How do differences in culture and values across countries/regions in the Asia-Pacific lead to differences in the methodology and use of HTA and economic evaluation for policy decisions?

Discussion Session III (Moderated by Dr. Yen-Huei (Tony) Tarn)

- Considering many issues surrounding new devices including investment costs and risks, uncertainties of assessment, regulatory obstacles, commercial viability, and coverage, etc, how can we effectively engage diverse stakeholders across the product lifecycle?
- What are the recent key trends of medical devices in the Asia-Pacific?
- How can ISPOR help your organization/country/region? What is the one thing you want most from ISPOR? What are your key takeaways from this Roundtable?